Clinical Study Brain MRI abnormalities in Brazilian patients with neuromyelitis optica Cíntia Elias Piresa, b, , , Christianne Martins Correa da Silvaa, Fernanda Cristina Rueda Lopesa, b, Fabiola Rachid Malfetanoa, Valéria C.S.R. Pereiraa, Tadeu Kubob, Paulo R.V. Bahiaa, Soniza Vieira Alves-Leona, Emerson L.
Neuromyelitis optica and pregnancy B. Bourre, MD, R. Marignier, MD, H
Background: Neuromyelitis optica is an autoimmune disease usually restricted to spinal cord and optic nerves. Recently, an immunological marker (NMO-IgG) directed against the aquaporin-4 (AQP4) has been found in this disease. Although it usefulness in NMO diagnosis was established, its correlation with disease activity and its interest for NMO follow up was not demonstrated yet
OBJECTIVE:To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO). METHODS: This was a chart review and telephone follow-up study of 99 patients with NMO spectrum of disorders (NMOSD) treated with azathioprine (1994-2009). NMOSD were NMO (2006 diagnostic criteria) or partial NMO forms (NMO-immunoglobulin G seropositive)
OBJECTIVE: To investigate serum uric acid (UA) levels and related clinical characteristics of neuromyelitis optica (NMO). METHODS: The serum uric acid levels were measured in 65 patients with NMO, compared to control groups which were 76 cases with multiple sclerosis (MS), 126 cases with cerebral vascular diseases (CVD) and 130 healthy controls (HC). The disability severity in NMO was assessed by the Expanded Disability Status Scale (EDSS).
Background: There are limited number of studies investigating efficacy and safety of plasma exchange (PLEX) in treating acute demyelinating diseases like Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO). In a randomised double-blind trial of PLEX in treating acute demyelinating attacks,42% of patients on active treatment had significant improvement compared to 5.9% on sham.
Background: Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disorder characterized by recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis(LETM). Lower urinary tract symptoms (LUTS) such as voiding dysfuntion are disturbing in LETM patients and has not been studied in this specific population
OBJECTIVE: In the present study, we examined some demographic and clinical features of Turkish LDDD patients and we compared these features with Turkish conventional MS patients, on the basis of demographic, clinical and immunological features. BACKGROUND: So called limited disseminated demyelinating diseases (LDDDs) includes optic neuritis (ON), transverse myelitis (TM), optic-spinal multiple sclerosis (OSMS) and neuromyelitis optica (NMO). OSMS and NMO select the involvement of optic nerve and spinal cord more than conventional multiple sclerosis (CMS)
Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years
Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years. Few data exist on patients with pediatric-onset NMO (p-NMO), with disease onset before age 18 years.
There are no specific treatments for patients with acute, severe neurological deficits caused by neuromyelitis optica (NMO) who fail to recover after treatment with high-dose corticosteroids. We evaluated the clinical response of anti-tuberculosis treatment (ATT) in patients suffering from steroid-refractory NMO, and investigated the correlation between NMO and tuberculous infection of the central nervous system (CNS)